Why is Bliss GVS Pharma falling/rising?

As of 07-Nov, Bliss GVS Pharma Ltd is experiencing a significant decline in its stock price, currently at 128.10, which reflects a decrease of 23.8 points or 15.67%. The stock has underperformed its sector by 15.49% today and has been on a consecutive downward trend for the last four days, resulting in a total decline of 18.36% during this period. The stock opened with a loss of 2.7% and reached an intraday low of Rs 125.1, indicating high volatility with an intraday fluctuation of 13.6%. Additionally, the stock is trading below all key moving averages and has seen a decrease in investor participation, with delivery volume dropping by 4.57% compared to the five-day average. While the company has a low debt-to-equity ratio and an attractive valuation with a PEG ratio of 0.7, its long-term growth prospects are poor, with net sales and operating profit growing at only 6.54% and 5.27% annually over the last five years, respectively. In the broader market context, Bliss GVS Pharma's performance over the past week shows a decline of 18.20%, contrasting sharply with the Sensex, which has only decreased by 0.86%. Over the past month, the stock has fallen by 16.22%, while the Sensex has risen by 1.57%. This stark difference highlights the stock's underperformance relative to the market. Furthermore, institutional investors have reduced their stake in the company by 0.53% in the previous quarter, indicating a lack of confidence from those with more resources to analyze the company's fundamentals. Overall, the combination of poor short-term performance, declining investor interest, and weak growth indicators contributes to the stock's downward trajectory.